Skip to content
The Diary of a CEOThe Diary of a CEO

Tyna Moore: Microdosing GLP-1 quietly heals the brain

Moore reframes Ozempic as a regenerative tool at micro doses; she explains how GLP-1 calms brain inflammation, heals the gut, and helped her chronic pain.

Dr. Tyna MooreguestSteven Bartletthost
Jul 4, 20241h 58mWatch on YouTube ↗

CHAPTERS

  1. 4:00 – 14:00

    Defining Naturopathic Medicine and Metabolic Root Causes

    Moore explains what a naturopathic physician is, how her training differs from conventional MDs, and why she focuses on metabolic health as the root of many chronic illnesses rather than on disease labels. She describes her mentor’s influence and the concept of getting patients into a ‘healing state’ so that regenerative therapies and the body’s own systems can work.

  2. 14:00 – 32:00

    A Personal Case Study: Saving Her Mother from Crohn’s Decline

    Moore recounts how she nearly missed her mother’s Crohn’s disease until it was life‑threatening, then used an aggressive naturopathic and regenerative protocol to pull her out of crisis. She later added microdosed semaglutide, describing dramatic improvements in gut stability, joint pain, cognition, and anxiety.

  3. 32:00 – 48:00

    Moore’s Own Health Journey: Autoimmunity, Pain, and GLP‑1 Discovery

    Moore shares her lifelong history of stomach aches, anxiety, and chronic pain, culminating in severe psoriatic arthritis and near‑suicidal desperation by 2021. After many failed interventions, she began researching GLP‑1 and neuroinflammation, leading her to experiment with semaglutide on herself, with unexpectedly profound results.

  4. 48:00 – 1:08:00

    What GLP‑1 and Ozempic Actually Are: Peptides, Mechanisms, and Effects

    The conversation shifts into GLP‑1 biology, explaining peptides, how semaglutide mimics endogenous GLP‑1, and its multiple actions on appetite, gastric emptying, insulin secretion, and brain function. Moore underscores that many obese and diabetic individuals are GLP‑1 deficient and that modern gut health compromises natural GLP‑1 production.

  5. 1:08:00 – 1:20:00

    Beyond Weight Loss: Regeneration, Cancer, Kidneys, and the Brain

    Moore outlines research she believes shows GLP‑1 agonists are broadly regenerative and protective: reducing cardiovascular events, improving kidney outcomes, aiding beta‑cell regeneration in early type 1 diabetes, and possibly lowering certain cancer risks. She stresses that many of these benefits appear independent of weight loss.

  6. 1:20:00 – 1:29:00

    Muscle, ‘Muscle Loss’ Myths, and the Importance of Strength Training

    Addressing fears that Ozempic causes muscle wasting, Moore differentiates between lean mass and true muscle tissue, arguing that rapid caloric restriction—via any method—costs muscle and that GLP‑1s may actually improve muscle health when used properly alongside strength training and adequate protein.

  7. 1:29:00 – 1:43:00

    Microdosing vs. Standard Dosing: How Much, How Often, and Why

    Using a physical demo, Moore contrasts conventional prefilled GLP‑1 pen dosing (0.25 mg escalating to ~2.4–2.5 mg weekly) with her microdosing approach using compounded semaglutide. She describes titrating based on symptom thresholds, cycling on/off to resensitize receptors, and always combining with other therapies and lifestyle changes.

  8. 1:43:00 – 1:51:00

    GLP‑1, Dopamine, and Addiction: Quieting the ‘Noise’

    Moore explains how GLP‑1 signaling in the brain affects dopaminergic reward pathways, not just appetite hormones like ghrelin and leptin. She shares anecdotal and early research hints of reduced alcohol abuse, smoking, compulsive eating, and even compulsive online shopping in patients on GLP‑1s, framing the drugs as reducing hedonic ‘noise’ and restoring control.

  9. 1:51:00 – 2:00:00

    Fertility Crisis, PCOS, and Metabolic Dysfunction

    The discussion widens to global fertility trends and the role of metabolic dysfunction, PCOS, and sperm decline. Moore argues that GLP‑1’s impact on metabolic health and PCOS makes it a potentially powerful tool amid rising IVF dependence, but only alongside major environmental and lifestyle corrections.

  10. 2:00:00 – 2:07:00

    The Toxic Soup: Food, Microbiome, Toxins, and Social Decay

    Moore paints a broad picture of the modern ‘toxic soup’: ultra‑processed foods engineered for overconsumption, widespread chemical exposure, antibiotic‑induced microbiome disruption, sedentary living, light deprivation, and loneliness. She argues that these drivers make metabolic dysfunction nearly inevitable and that GLP‑1s are only one part of a much larger corrective effort.

  11. 2:07:00 – 2:18:00

    Six Pillars for a Pain‑Free, Metabolically Healthy Life

    Drawing from her book, Moore outlines practical pillars—strength training, movement, nutrition, sleep, mindset, and hormetic stressors like heat—that she believes are foundational for resolving chronic pain and disease. She argues that without these, no drug, including GLP‑1s, will produce durable health.

  12. 2:18:00 – 2:30:00

    Risk, Reward, and the Ethics of Using GLP‑1

    Moore addresses concerns that we lack long‑term safety data on microdosing and reiterates the need for risk–benefit analysis. She argues that the risks of staying in chronic inflammation and metabolic collapse often outweigh the theoretical risks of low‑dose GLP‑1, especially when monitored, while warning strongly against DIY experimentation.

  13. 2:30:00

    Closing Reflections: Responsibility, Curiosity, and Telling Unpopular Truths

    In closing, Moore and Bartlett discuss intellectual humility, seeking knowledge, and being willing to challenge consensus. Moore says she’s proudest of choosing a hard path to tell early, unpopular truths for patients’ benefit and urges audiences to independently verify claims rather than following influencers or headlines.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome